Treatment With A Carboplatin-Based Doublet Plus Bevacizumab Beyond Disease Progression Significantly Improved Progression-Free Survival Vs A Carboplatin-Based Doublet Alone In Women With Platinum-Sensitive Ovarian Cancer In Phase 3 Trial

The ASCO Post (2/23, Stenger) reports researchers found in the phase 3 MITO16b/MANGO-OV2/ENGOT-ov17 trial “found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer who experienced disease recurrence after first-line treatment with a platinum-based therapy plus bevacizumab.” The trial’s results were published in […]

Read More

Researchers Identify Genetic Changes In Tumors That May Predict Efficacy Of Immunotherapy Drugs

Medscape (2/10, Nelson, Subscription Publication) reports researchers in the UK “have identified genetic changes in tumors that could be used to predict whether immunotherapy drugs will be effective in a given patient.” The researchers “found that the number of genetic mutations present in cancer cells was the best predictor of tumor response to immunotherapy with checkpoint inhibitors,” […]

Read More

Researchers Say Psychological Response To Genetic Counseling And Multigene Panel Testing For Hereditary Cancer Risk Tied To Test Results And Demonstrated Low Distress And Uncertainty

Cancer Network (2/9, Slater) reports researchers found that “among an ethnically and socioeconomically diverse population of individuals undergoing genetic counseling and multigene panel testing for hereditary cancer risk…psychological response corresponded to test results and demonstrated low distress and uncertainty.” The findings were published in Cancer. […]

Read More

Researchers Examine Prevalence, Risk Factors, And Prognostic Value Of Chemotherapy-Associated VTE In Patients With Ovarian Cancer

Cancer Network (2/8, Fowler) reports researchers examined “the prevalence, risk factors, and prognostic value of chemotherapy-associated venous thromboembolism (VTE) in patients with ovarian cancer” and “found a pooled prevalence of 9% for this group of patients.” In addition, “the data also found substantial risk factors for chemotherapy-related VTE, potentially assisting future efforts to target preventative measures […]

Read More

Oral Contraceptive Use Associated With Decreased Risk Of Ovarian Cancer, Endometrial Cancer Three Decades After Discontinuation

MD Edge ObGyn (2/3, Remaly) reports, “Oral contraceptive use is associated with a decreased risk of ovarian and endometrial cancer 3 decades after discontinuation, according to an analysis of data from more than 250,000 women.” Furthermore, “oral contraceptive use is associated with a short-term increased risk of breast cancer after discontinuation, although the lifetime risk of […]

Read More

MRI Can Be Used To Assess Cervical Neuroendocrine Carcinoma

Diagnostic Imaging (2/2, Palmer) reports a new study suggests MRI can be used to identify and accurately assess neuroendocrine carcinoma (NEC) in the uterine cervix. Researchers in Japan “enrolled 62 women, ranging from ages 26 to 82, who had histologically surgery-proven uterine cervical NEC, and examined them with T2-weighted MRI,” determining that “among the 50 women in […]

Read More

Majority Of Patients With Cancer Are Unfamiliar With Complementary, Integrative Therapies

The ASCO Post (2/1, Stenger) reports a single-institution study at the University Hospitals Seidman Cancer Center in Cleveland, Ohio “found that a high proportion of patients with cancer and their caregivers were unfamiliar with available complementary and integrative medicine services.” Patients were surveyed “about five complementary and integrative medicine therapies – acupuncture, massage, meditation, music therapy, and yoga,” […]

Read More

Addition Of Wee1 Inhibitor To Gemcitabine Reduces Risk Of Disease Progression And Death In Women With Recurrent, Platinum-Resistant Or -Refractory Ovarian Cancer In Phase 2 Trial

MedPage Today (1/25, Ingram) reports researchers found in a phase 2 trial that the addition of “the Wee1 inhibitor adavosertib to gemcitabine reduced the risk of disease progression and death in women with recurrent, platinum-resistant or -refractory ovarian cancer.” The trial’s results were published in The Lancet. […]

Read More

US Reports Another Record One-Year Decline In Cancer Death Rate From 2017 To 2018

The AP (1/12, Stobbe) reports the US “reported another record one-year decline in the…cancer death rate, a drop they attribute to success against lung cancer.” The US cancer death rate has been decreasing since 1991, and “from 2017 to 2018, it fell 2.4%, according to an American Cancer Society report, topping the record 2.2% drop reported the year […]

Read More

CRT Improves DFS And OS In Patients With Stage IIIB Cervical Cancer In Long-Term Follow-Up To Phase 3 Trial

Cancer Therapy Advisor (1/7, Lawrence) reports researchers found in a long-term follow-up of a phase 3 trial that “in addition to improving disease-free survival (DFS), chemoradiotherapy (CRT) resulted in an overall survival (OS) benefit for patients with stage IIIB cervical cancer.” The researchers say the results “reinforce the evidence that CRT for the treatment of stage […]

Read More